Skip to main content
. 2021 Apr 7;11:7614. doi: 10.1038/s41598-021-87289-6

Figure 3.

Figure 3

Performance of platform-based antibody tests using consecutively collected samples from 38 COVID-19 patients. The samples (n = 86) were collected during week 1–7 after onset of symptom. Weeks 1–7 are represented by 15, 26, 19, 9, 7, 6, and 4 samples, respectively. Due to a limitation in sample volumes, Abbott was evaluated using a subset of the samples (n = 78). Samples with a borderline outcome were considered negative.